查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916929

寡核苷酸疗法市场按治疗领域、技术、寡核苷酸化学、递送方法、给药途径、产品类型和最终用户划分－2026-2032年全球预测

Oligonucleotide Therapeutics Market by Therapeutic Area, Technology, Oligonucleotide Chemistry, Delivery Method, Route Of Administration, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，寡核苷酸疗法市场价值将达到 223.4 亿美元，到 2026 年将成长至 237.3 亿美元，复合年增长率为 6.90%，到 2032 年将达到 356.5 亿美元。

关键市场统计数据
基准年 2025 223.4亿美元
预计年份：2026年 237.3亿美元
预测年份 2032 356.5亿美元
复合年增长率 (%) 6.90%

明确阐述不断发展的化学、递送平台、监管动态和商业策略如何重塑寡核苷酸疗法

寡核苷酸疗法已从一项科学创新发展成为精准医疗的核心支柱，这得益于其不断提升的临床疗效和技术成熟度。过去十年间，化学修饰、递送载体和标靶定序技术的进步，使得反义寡核苷酸、siRNA、miRNA调变器相关疗法从小众研究工具发展成为多种疾病领域的实用治疗选择。本文概述了目前的研究现状、影响其应用推广的科学和商业性因素，以及相关人员为实现持续价值所必须克服的关键转折点。

核苷酸化学、递送方式、临床检验和策略合作的最新进展正在共同重塑治疗的可能性。

寡核苷酸疗法领域正经历着由科学突破和商业性需求共同驱动的变革。诸如锁核酸、胜肽核酸和新一代硫代磷酸酯骨架等化学创新显着提高了核酸酶抗性和靶向特异性，拓宽了治疗窗口并降低了给药频率。同时，递送技术也突破了全身暴露的限制，发展出更为精准的递送方式，例如用于肝臟标靶化的GalNAc偶联、可实现广泛组织分布的改良脂质奈米颗粒，以及用于中枢神经系统和眼科的特异性病毒和非病毒载体。这些技术进步使研发人员能够将以往难以攻克的标靶转化为可行的治疗性介入。

评估美国关税政策变化在2025年前对寡核苷酸研发供应链、采购和製造韧性的营运和策略影响

2025年，美国关税政策变化带来的累积影响，正日益增加寡核苷酸疗法研发和生产商的营运及策略复杂性。影响关键投入品（例如特种核苷亚磷酰胺、修饰核苷酸和特定试剂盒）的关税，推高了外包合成和内部生产的成本。为此，供应链管理人员正越来越多地实施供应商优化、双源采购策略，并提高对上游投入品的透明度，以降低风险并确保关键计划的连续性。这些调整优先考虑供应商合格和长期合约的签订，而非短期价格最佳化。

全面的細項分析揭示了治疗标靶、技术类别、化学选择、递送途径、给药途径、最终用户和产品类型之间的相互作用。

从细緻的细分观点，不同治疗标靶、技术类型、化学选择、给药途径、给药方法、最终用户和产品类型所带来的机会和技术要求各不相同。按治疗领域划分，项目涵盖心血管疾病、感染疾病、代谢性疾病治疗、神经病学（重点关注阿兹海默症、Duchenne氏肌肉失养症和亨廷顿病）、肿瘤学（包括骨髓恶性肿瘤和固态肿瘤） 、眼科以及丛集罕见疾病治疗，例如β-地中海贫血、遗传性高胆固醇症和脊髓性肌萎缩症。这些治疗领域的差异影响着标靶检验策略、患者群体可及性考量以及监管路径。

详细分析美洲、欧洲、中东和非洲以及亚太地区的区域趋势，以及监管合规、製造地和市场进入的战略要务。

区域趋势显着影响寡核苷酸疗法的研发重点、监管路径、报销环境和供应链策略。在美洲，监管机构正日益透过加速核准支持针对严重和危及生命的疾病的新型治疗方法，而商业生态系统则强调生物技术公司与契约製造之间的合作，以加速从临床到商业化的转化。该地区的劳动力市场、投资者兴趣和完善的製药基础设施有利于临床项目的快速迭代，但研发人员必须应对不同支付方和政府系统报销政策的差异。

专有化学技术、递送平台、生产能力和策略合作伙伴关係如何帮助寡核苷酸疗法领域建立可持续的竞争优势

寡核苷酸疗法生态系统中的竞争优势取决于专有化学技术、递送平台、卓越的生产製造流程和策略联盟的结合。主要企业透过持续投资平台知识产权来实现差异化，例如透过化学修饰支架改善药物动力学，或开发实现组织特异性的递送偶联物。同时，合约开发和生产机构 (CDMO) 提供从大规模固相合成到先进纯化和分析测试等专业的寡核苷酸技术，是加速产品研发管线和确保商业化供应的关键促进者。

切实可行、影响深远的策略行动，旨在帮助企业强化平台、保障供应链安全、吸引早期支付者并扩大寡核苷酸专案的生产规模。

产业领导者可以采取切实可行的措施，在寡核苷酸疗法领域获得策略优势并加速专案成熟。首先，投资差异化平台，将优化的化学方法与检验的递送系统结合，以降低研发风险并创建更清晰的监管路径。其次，优先考虑供应链的韧性，具体措施包括：对关键原材料的多个供应商进行资格认证；考虑区域性製造地以降低贸易风险；以及签订长期采购协议，使合作伙伴之间的奖励保持一致。

采用严谨的混合调查方法方法，结合专家访谈、文献回顾、专利分析和情境检验，为策略决策提供支援。

本分析的调查方法结合了多层次的证据综合与检验。主要研究包括对药物发现、临床开发、监管事务和生产领域的专家进行结构化访谈，以及与参与寡核苷酸计划的采购和供应链经理进行咨询。次要研究整合了同行评审文献、监管指导文件和专利申请，以追踪技术演进轨迹并识别持续存在的技术挑战。交叉检验工作将定性研究结果与监管先例和生产实践进行比较，以确保其可靠性。

概述重点指出，整合技术、营运和商业性策略将决定哪些寡核苷酸计画能够拓展到永续的治疗领域。

总之，寡核苷酸疗法正处于一个转折点，科学进步、递送方式改进、化学技术日趋成熟以及法规结构的不断完善正在汇聚，共同开拓新的治疗领域。技术创新与商业策略的结合已成为决定哪些项目能够成功从概念验证过渡到永续治疗产品线的关键因素。那些能够整合平台差异化、供应链韧性、监管前瞻性和生产规模的企业，将更有利于获取长期价值。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 寡核苷酸疗法市场依治疗领域划分

  • 循环系统
  • 感染疾病
  • 代谢性疾病
  • 神经病学
    • 阿兹海默症
    • Duchenne氏肌肉失养症
    • 亨丁顿舞蹈症
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤
  • 眼科
  • 罕见疾病
    • β-地中海型贫血
    • 遗传性高胆固醇症
    • 脊髓性肌肉萎缩症

9. 按技术分類的寡核苷酸疗法市场

  • 反义寡核苷酸
    • RNase H 依赖型
    • 空间位阻
  • 适体
  • CpG寡脱氧核苷酸
  • miRNA
    • 微型RNA抑制剂
    • miRNA模拟物
  • siRNA
    • 化学改性
    • 不合格的

10. 寡核苷酸治疗市场（依寡核苷酸化学分类）

  • 2'-O-甲基RNA
  • 锁核酸
  • 吗啉代寡聚物
  • 胜肽核酸
  • 硫代磷酸酯寡核苷酸

第十一章 寡核苷酸疗法市场依给药方式划分

  • 共轭物
  • 直接注射
  • 电穿孔
  • 脂质奈米颗粒
  • 病毒载体

12. 寡核苷酸疗法市场依给药途径划分

  • 吸入
  • 肌肉内注射
  • 静脉注射
  • 口服
  • 皮下注射

13. 寡核苷酸疗法市场（依产品类型划分）

  • 诊断试剂
  • 研究试剂
  • 治疗药物

第十四章 寡核苷酸疗法市场（以最终用户划分）

  • 门诊治疗中心
  • 医院
  • 製药公司
  • 研究所

15. 各地区寡核苷酸疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 寡核苷酸疗法市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国寡核苷酸疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国寡核苷酸疗法市场

第十九章 中国寡核苷酸疗法市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Biogen Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Nitto Denko Avecia, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regulus Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-AE420CB153FF

The Oligonucleotide Therapeutics Market was valued at USD 22.34 billion in 2025 and is projected to grow to USD 23.73 billion in 2026, with a CAGR of 6.90%, reaching USD 35.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.34 billion
Estimated Year [2026] USD 23.73 billion
Forecast Year [2032] USD 35.65 billion
CAGR (%) 6.90%

A crisp orientation to how evolving chemistry, delivery platforms, regulatory evolution, and commercial strategy are reshaping oligonucleotide therapeutics

Oligonucleotide therapeutics have moved from scientific novelty to a central pillar of precision medicine portfolios, driven by expanding clinical validation and technological maturation. Over the past decade, advances in chemical modification, delivery vehicles, and targeted sequencing have elevated antisense oligonucleotides, siRNA, miRNA modulators, and related modalities from niche investigational tools to viable therapeutic options across multiple disease classes. This introduction outlines the current landscape, the scientific and commercial drivers shaping adoption, and the critical inflection points that industry stakeholders must navigate to realize durable value.

The field now integrates sophisticated nucleotide chemistries that enhance stability and target affinity with delivery strategies that broaden tissue reach beyond the liver. Regulatory frameworks have evolved in parallel, accommodating expedited pathways for severe and rare diseases while imposing rigorous manufacturing and quality standards. Simultaneously, biopharma and contract development organizations are investing in scalable synthesis and analytical platforms to address the unique production challenges of oligonucleotides. Consequently, corporate strategies increasingly emphasize platform differentiation, intellectual property stewardship, and strategic alliances to combine therapeutic expertise with delivery innovation.

As the modality crosses therapeutic boundaries from neurology and rare genetic disorders into oncology and metabolic disease, stakeholders must balance therapeutic ambition with pragmatic operational planning. This introduction sets the stage for a deeper analysis of transformative shifts, trade policy impacts, segmentation nuance, regional dynamics, competitive positioning, and recommended actions for leaders seeking to capitalize on the maturation of oligonucleotide therapeutics.

How recent advances in nucleotide chemistries, delivery modalities, clinical validation, and strategic partnerships are collectively redefining therapeutic possibilities

The landscape for oligonucleotide therapeutics is experiencing transformative shifts driven by converging scientific breakthroughs and commercial imperatives. Chemical innovations such as locked nucleic acids, peptide nucleic acids, and next-generation phosphorothioate backbones have materially improved nuclease resistance and target specificity, thereby extending therapeutic windows and reducing dosing frequency. Concurrently, delivery technologies have advanced from systemic exposure constraints to more precise approaches including GalNAc conjugation for hepatic targeting, lipid nanoparticle refinements that permit broader tissue distribution, and viral or non-viral vectors tailored for central nervous system and ocular delivery. These technical strides are enabling developers to reframe previously intractable targets as achievable therapeutic interventions.

At the same time, the clinical evidence base has shifted perceptions of feasibility across therapeutic areas. Neurology has emerged as a proving ground for central nervous system delivery strategies, while oncology programs increasingly leverage oligonucleotide constructs to modulate oncogenic drivers and immune pathways. The development ecosystem is also evolving: strategic partnerships between biotech innovators and established pharmaceutical manufacturers are becoming more transactional and purpose-built, focusing on rapid scale-up, supply continuity, and regulatory alignment. Investment patterns reflect a maturing ecosystem, with capital directed not only to clinical-stage assets but also to platform technologies and manufacturing capacity expansions that underpin long-term commercialization.

These shifts create both opportunity and complexity. Organizations that synchronize chemistry innovation with scalable delivery and robust manufacturing will gain competitive advantage, while those that underestimate regulatory expectations, quality control demands, and the intricacies of tissue-specific delivery risk costly setbacks. The cumulative effect is a market in transition, where technological differentiation and operational excellence jointly determine the trajectory of therapeutic success.

Evaluating the operational and strategic consequences of United States tariff policy shifts through 2025 on supply chains, sourcing, and manufacturing resilience in oligonucleotide development

The cumulative effects of tariff policy changes in the United States through 2025 have introduced an additional layer of operational and strategic complexity for developers and manufacturers of oligonucleotide therapeutics. Tariffs affecting key inputs such as specialized nucleoside phosphoramidites, modified nucleotides, and certain reagent classes have increased the cost base for outsourced synthesis and in-house production. In response, supply chain managers have intensified supplier rationalization, dual-sourcing strategies, and visibility into upstream inputs to mitigate risk and preserve continuity for critical campaigns. These adaptations have prioritized supplier qualification and long-term contractual commitments over short-term price optimization.

Tariff-driven inflation of input costs has also accelerated interest in regional manufacturing investments and capacity reallocation. Firms evaluating capital allocation decisions weigh the trade-offs between higher near-term capital expenditures for local production and the long-term benefits of supply security, regulatory alignment, and reduced exposure to cross-border trade frictions. At the same time, clinical development timelines can be sensitive to reagent and consumable availability, making procurement lead times an operational imperative rather than a back-office concern.

Policy volatility has pushed some organizations to reassess externalization strategies, favoring integrated partnerships that include upstream raw material sourcing and tiered supply agreements. Additionally, procurement and finance functions are collaborating more closely with R&D and manufacturing to model tariff scenarios and embed contingency plans into project timelines. While tariffs create headwinds, they also catalyze structural adjustments that can strengthen resilience and encourage investment in manufacturing sophistication and domestic supply capability.

Comprehensive segmentation analysis revealing how therapeutic focus, technology class, chemistry choices, delivery routes, administration pathways, end users, and product types interact

A nuanced segmentation lens reveals differentiated opportunities and technical requirements across therapeutic targets, technology types, chemistry options, delivery routes, administration modalities, end-users, and product categories. When segmented by therapeutic area, programs span cardiovascular disease, infectious disease, metabolic disorder interventions, neurology with focused attention on Alzheimer's disease, Duchenne muscular dystrophy, and Huntington's disease, oncology addressing both hematological malignancies and solid tumors, ophthalmology initiatives, and a cluster of rare disease approaches that include beta thalassemia, familial hypercholesterolemia, and spinal muscular atrophy. These therapeutic distinctions shape target validation strategies, patient population access considerations, and regulatory pathways.

Breaking down the landscape by technology, the field encompasses antisense oligonucleotides-distinguished by RNase H dependent mechanisms and steric blocking modalities-aptamers, CpG oligodeoxynucleotides, microRNA therapeutics encompassing both inhibitors and mimics, and siRNA constructs that range from chemically modified to unmodified forms. Each technology class imposes unique demands on design optimization, potency thresholds, and safety profiling. Chemistry selection further refines those demands: options such as 2'-O-methyl RNA, locked nucleic acids, morpholino oligomers, peptide nucleic acids, and phosphorothioate oligonucleotides present trade-offs among stability, affinity, immunogenicity, and manufacturability.

Delivery method segmentation includes conjugates, direct injection approaches, electroporation, lipid nanoparticles, and viral vectors, while routes of administration range from inhalation and intramuscular to intravenous, oral, and subcutaneous delivery. End users span ambulatory care centers, hospitals, pharmaceutical companies, and research institutes, each with distinct procurement models, infrastructure needs, and regulatory expectations. Product types differentiate diagnostics, research reagents, and therapeutic assets, which in turn influence commercialization strategies, reimbursement considerations, and manufacturing quality systems. Integrating these segmentation layers enables targeted portfolio planning and more precise go-to-market strategies aligned with technical feasibility and clinical priorities.

Detailed regional dynamics and strategic imperatives for regulatory engagement, manufacturing placement, and market access across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence development priorities, regulatory pathways, reimbursement landscapes, and supply chain strategies for oligonucleotide therapeutics. In the Americas, regulatory agencies have increasingly accommodated novel modalities through expedited pathways for serious and life-limiting conditions, and commercial ecosystems emphasize partnerships between biotech innovators and contract manufacturers to accelerate clinical-to-commercial transitions. The labor market, investor appetite, and established pharma infrastructure in the region drive rapid iteration of clinical programs, though developers must navigate reimbursement variability across payers and public systems.

Europe, Middle East & Africa presents a mosaic of regulatory regimes where centralized approval pathways coexist with country-level access constraints. Stakeholders operating across this region contend with heterogenous pricing and reimbursement frameworks, divergent clinical practice patterns, and varying levels of manufacturing capacity. Consequently, market access strategies require sophisticated evidence generation plans and early engagement with payers and health technology assessment bodies to align clinical endpoints with value demonstration.

Asia-Pacific combines rapidly growing biotech hubs with region-specific scientific strengths and manufacturing scale. Several countries in the region have invested in capacity expansion for oligonucleotide synthesis and biologics manufacturing, offering competitive cost structures and strong technical talent pools. However, differences in regulatory expectations and clinical trial infrastructure necessitate adaptive development strategies and localized regulatory affairs expertise. Together, these regional contours demand that developers tailor clinical, manufacturing, and commercial plans to reflect distinct regulatory regimes, payer landscapes, and supply chain realities.

How proprietary chemistries, delivery platforms, manufacturing capability, and strategic alliances are creating durable competitive moats in oligonucleotide therapeutics

Competitive positioning in the oligonucleotide therapeutics ecosystem is defined by a combination of proprietary chemistries, delivery platforms, manufacturing excellence, and strategic partnerships. Leading organizations differentiate through sustained investment in platform intellectual property, whether that is a chemically modified backbone that improves pharmacokinetics or a delivery conjugate that enables tissue specificity. At the same time, contract development and manufacturing organizations that offer specialized oligonucleotide capabilities-from large-scale solid-phase synthesis to advanced purification and analytical testing-serve as critical enablers for pipeline acceleration and commercial supply.

Strategic alliances between small biotech innovators and larger pharmaceutical or manufacturing partners have become a prevalent model to bridge capability gaps, while mergers and acquisitions continue to reconfigure competitive landscapes by consolidating platform technologies or bolstering manufacturing scale. Companies with integrated capabilities that span discovery, manufacturing, and regulatory affairs gain an advantage in compressing time-to-clinic and de-risking later-stage development. Conversely, firms that rely excessively on single-source suppliers or narrow technology portfolios face heightened vulnerability to supply disruptions and competitive displacement.

A resilient competitive strategy now also incorporates talent acquisition in specialized disciplines such as oligonucleotide analytics, regulatory science for nucleotide therapeutics, and GMP manufacturing of modified nucleotides. Organizations that cultivate cross-functional expertise and embed continuous process improvement within quality systems are better positioned to translate scientific innovation into reliable, scalable commercial outcomes.

Practical, high-impact strategic actions for companies to strengthen platforms, secure supply chains, engage payers early, and scale manufacturing for oligonucleotide programs

Industry leaders can take specific, actionable steps to secure strategic advantage and accelerate program maturation within the oligonucleotide therapeutics domain. First, invest in platform differentiation that pairs optimized chemistries with validated delivery systems to reduce development risk and create clearer regulatory pathways. Second, prioritize supply chain resilience by qualifying multiple suppliers for critical raw materials, considering regional manufacturing footprints to mitigate trade exposure, and establishing long-term procurement agreements that align incentives across partners.

Third, embed regulatory and payer engagement early in program design to ensure that clinical endpoints and evidence generation plans anticipate real-world access considerations. Fourth, cultivate strategic partnerships that close capability gaps-particularly in large-scale synthesis, advanced analytics, and specialized delivery vectors-rather than relying solely on ad hoc contracting. Fifth, develop integrated talent strategies to attract and retain expertise in oligonucleotide chemistry, GMP production, and regulatory science, while investing in continuous training and knowledge transfer mechanisms. Finally, adopt agile project management and scenario planning to respond quickly to policy shifts, supply chain disruptions, and competitive moves, thereby preserving runway and protecting program timelines.

Taken together, these recommendations form a coherent playbook for organizations seeking to convert scientific breakthroughs into sustainable therapeutic franchises, balancing innovation with operational rigor and commercial foresight.

A rigorous mixed-methods research methodology combining expert interviews, literature synthesis, patent analysis, and scenario-based validation to support strategic decision making

The research methodology underpinning this analysis combined a layered approach to evidence synthesis and validation. Primary research included structured interviews with domain experts across discovery, clinical development, regulatory affairs, and manufacturing as well as consultations with procurement and supply chain leads involved in oligonucleotide projects. Secondary research integrated peer-reviewed literature, regulatory guidance documents, and patent filings to trace technology evolution and identify enduring technical challenges. Cross-validation exercises compared qualitative insights with regulatory precedent and manufacturing practice to ensure robustness.

Analytical methods involved thematic coding of expert interview data to reveal recurring operational risks and strategic priorities, followed by scenario analysis to map the implications of tariff shifts, delivery breakthroughs, and regulatory changes. Technology readiness assessments were used to appraise the maturity of chemistries and delivery modalities, and capability gap analyses evaluated where investment would most effectively reduce development risk. All findings were synthesized into actionable recommendations and risk mitigation frameworks intended for executive stakeholders and technical teams alike.

Quality assurance processes included triangulation across multiple data sources, peer review by independent domain specialists, and iterative revisions based on stakeholder feedback. The methodology emphasizes transparency in assumptions, traceability of evidence, and pragmatic framing of recommendations to facilitate decision-making under uncertainty.

Concluding synthesis emphasizing how integrated technical, operational, and commercial strategies will determine which oligonucleotide programs scale into enduring therapeutic franchises

In conclusion, oligonucleotide therapeutics stand at an inflection point where scientific progress, improved delivery modalities, refined chemistries, and evolving regulatory frameworks collectively unlock new therapeutic territories. The intersection of technical innovation and commercial strategy is now the primary determinant of which programs will successfully transition from proof-of-concept to sustainable therapeutic franchises. Organizations that integrate platform differentiation, supply chain resilience, regulatory foresight, and manufacturing scale will be best positioned to capture long-term value.

Policy factors such as tariff changes and regional regulatory variability have heightened the importance of operational planning and localized strategy. Meanwhile, segmentation insights across therapeutic areas, technologies, chemistries, delivery routes, administration types, end users, and product categories reveal that a one-size-fits-all approach is no longer viable. Instead, targeted, data-informed strategies that align scientific feasibility with real-world access and manufacturing realities are essential.

Ultimately, the pathway to success requires balancing ambitious clinical goals with disciplined execution. Stakeholders that move decisively to shore up technical, operational, and commercial capabilities will find themselves well placed to lead the next wave of oligonucleotide therapeutic innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oligonucleotide Therapeutics Market, by Therapeutic Area

  • 8.1. Cardiovascular
  • 8.2. Infectious Diseases
  • 8.3. Metabolic Disorders
  • 8.4. Neurology
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Duchenne Muscular Dystrophy
    • 8.4.3. Huntington's Disease
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Solid Tumors
  • 8.6. Ophthalmology
  • 8.7. Rare Diseases
    • 8.7.1. Beta Thalassemia
    • 8.7.2. Familial Hypercholesterolemia
    • 8.7.3. Spinal Muscular Atrophy

9. Oligonucleotide Therapeutics Market, by Technology

  • 9.1. Antisense Oligonucleotide
    • 9.1.1. RNase H Dependent
    • 9.1.2. Steric Blocking
  • 9.2. Aptamer
  • 9.3. CpG Oligodeoxynucleotide
  • 9.4. Mirna
    • 9.4.1. Mirna Inhibitors
    • 9.4.2. Mirna Mimics
  • 9.5. Sirna
    • 9.5.1. Chemically Modified
    • 9.5.2. Unmodified

10. Oligonucleotide Therapeutics Market, by Oligonucleotide Chemistry

  • 10.1. 2'-O-Methyl RNA
  • 10.2. Locked Nucleic Acid
  • 10.3. Morpholino Oligomers
  • 10.4. Peptide Nucleic Acid
  • 10.5. Phosphorothioate Oligonucleotides

11. Oligonucleotide Therapeutics Market, by Delivery Method

  • 11.1. Conjugates
  • 11.2. Direct Injection
  • 11.3. Electroporation
  • 11.4. Lipid Nanoparticles
  • 11.5. Viral Vectors

12. Oligonucleotide Therapeutics Market, by Route Of Administration

  • 12.1. Inhalation
  • 12.2. Intramuscular
  • 12.3. Intravenous
  • 12.4. Oral
  • 12.5. Subcutaneous

13. Oligonucleotide Therapeutics Market, by Product Type

  • 13.1. Diagnostics
  • 13.2. Research Reagents
  • 13.3. Therapeutics

14. Oligonucleotide Therapeutics Market, by End User

  • 14.1. Ambulatory Care Centers
  • 14.2. Hospitals
  • 14.3. Pharmaceutical Companies
  • 14.4. Research Institutes

15. Oligonucleotide Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Oligonucleotide Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Oligonucleotide Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Oligonucleotide Therapeutics Market

19. China Oligonucleotide Therapeutics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Agilent Technologies, Inc.
  • 20.6. Alnylam Pharmaceuticals, Inc.
  • 20.7. Arrowhead Pharmaceuticals, Inc.
  • 20.8. Biogen Inc.
  • 20.9. Dicerna Pharmaceuticals, Inc.
  • 20.10. Gilead Sciences, Inc.
  • 20.11. Ionis Pharmaceuticals, Inc.
  • 20.12. Merck & Co., Inc.
  • 20.13. Merck KGaA
  • 20.14. Moderna, Inc.
  • 20.15. Nitto Denko Avecia, Inc.
  • 20.16. Novartis AG
  • 20.17. Pfizer Inc.
  • 20.18. Regulus Therapeutics, Inc.
  • 20.19. Sarepta Therapeutics, Inc.
  • 20.20. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY BETA THALASSEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY BETA THALASSEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RNASE H DEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RNASE H DEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RNASE H DEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY STERIC BLOCKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY STERIC BLOCKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY STERIC BLOCKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY APTAMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY APTAMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY APTAMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CPG OLIGODEOXYNUCLEOTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CPG OLIGODEOXYNUCLEOTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CPG OLIGODEOXYNUCLEOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA MIMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA MIMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA MIMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CHEMICALLY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CHEMICALLY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CHEMICALLY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY UNMODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY UNMODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY UNMODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY 2'-O-METHYL RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY 2'-O-METHYL RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY 2'-O-METHYL RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LOCKED NUCLEIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LOCKED NUCLEIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LOCKED NUCLEIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MORPHOLINO OLIGOMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MORPHOLINO OLIGOMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MORPHOLINO OLIGOMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE NUCLEIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE NUCLEIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE NUCLEIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIRECT INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIRECT INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 289. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 294. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 295. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 296. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVE